DEUTSCHE AIDS-HILFE e. V.
Issue 11/1998 of 08/06/1998
Introductory remark
In regard with so called "alternative" medicaments there has been a
discussion going on for some time about a preparation called "TODoXIN".
There is too little information on the effectiveness of this
preparation, but the articles are circulating on the topic of "the
medicine: 'TODoXIN'" expressing excitement or rejection. As far as
we know, there are no underpinned contributions in which all the
knowledge would be critically worked out and summarized. By the
following detailed article we wish to fill this gap.
Introduction
"TODoXIN" is a herbal remedy which has been applied on over 7,000
patients in the cases of different (oncogen) viruses and against
HIV-infection effects for 10 years. It was developed by Dr. Todor
Jovanovic, a physician born in Vrani Do, Kosovo, in 1935. Dr.
Jovanovic studied medicine in Belgrade and finished his
specialization in Allergology. After the graduation he carried out
research in the UN Research Centre for Nuclear Medicine and in
military research centre in Vinca, near Belgrade. The main field of
the research was search for histocompatible materials for implantats.
Another field of intensive work was the research and monitoring of
immunostimulating effects of plant extracts.
In 1987, Dr. Jovanovic applied for a patent on TODoXIN recipe. After
that, he made an effort to get the support of experts and
institutions in the country and abroad for his projects. There were,
among others, the president of Serbian Academy of Science and Art,
Dusan Kanazir, Luk Montagnier, the man who discovered HIV, as well
as the leader of the special program of WHO for AIDS, Jonathan
Man.
Because of the sparse data, no one showed interest for that project,
except for the leader of a research group from Austria. With the
Austrian partners in the research, Dr. Jovanovic signed a long-term
contract on cooperation in 1988. The goal of the cooperation was to
test the remedy on the international scale, galenic development and
later, submission of the appropriate study results, obtaining the
international approval and production.
After it has been proved toxicologically safe in 1988, the Austrian
team, in collaboration with the Karolinska Institute for Immunology
in Stockholm, in 1988-89, succeeded in showing the immunostimulating
properties of TODoXIN in vitro, as well as the development of
pharmacodynamic model of effect mechanisms induced on the
immuoendocrinal level. That model could have been tested ex vitro
and and confirmed in vivo. It was followed by intensive medical
observation of its use, in collaboration with some clinical workers
and physicians, in a wide spectrum of potential indications for
immunostimulating properties of TODoXIN. On the basis of the data
obtained by early 1991, the scientists of National Institutes of
Health (NIH), in Washington, expressed their readiness to examine
TODoXIN in vitro within the "Developmental Therapeutics Program".
The studies of HIV culturing proved that cell bearable
concentrations of active agents of TODoXIN can inhibit HIV up to
100%.
At the end of 1991 TODoXIN was given the license for production in
Yugoslavia under the register number 4684 dd 31/10/88, as a
"dietetic product based on honey and medicinal herbs ". The records
on HIV- inhibiting capacity of TODoXIN, obtained at NIH, as well as
the results of HIV-positive patients treated with TODoXIN since
1988, were not presented until the 10th International Conference on
AIDS in Yokohama (1994), because NIH which was late in giving the
permission for releasing the data.
On the basis of these data the Austrian research group succeeded in
winning over the European virologists and AIDS researchers, prof.
Richard Teddar and Dr. Clive Loveday from UCL Medical School of
London, to the scientific collaboration. The data jointly won over
the years that followed were appraised and designated as “very
promising" by members of the British Medical Research Council – MRC
and HIV Clinical Trial Centre – prof. A. Brackenridge, prof. D.
Jeefries, prof. I. Weller and Dr J. Darbyshire.
On the 11. International AIDS Conference in Vancouver (1996), an
official symposium on TODoXIN was held, where the most recent data
were presented.
After that, the Department for Retro virology of Royal Free Medical
School in London came up with offer to carry out further studies in
England under official supervision of pharmaceutical authorities,
MRC and one ethical committee. The results of these studies were
supposed to support the official request for registration of TODoXIN
in the European Union. The study started, after longer preparations,
in September 1997, after it had been established that TODoXIN is to
be produced in the future by Dr. Jovanovic together with an Austrian
partner in the research, within one Austrian firm.
In the course of the study, Dr. Jovanovic decided to accept the
offers of English researchers and their American partners to have
TODoXIN produced in the USA in the future and to carry out further
study over there. In order to present data which were up-to-date in
1998. to American partners, the London study, started in 1997, was
interrupted in March 1998, and a new study was started, using the
first laboratory samples of American TODoXIN. A separate American
study is still about to start this year in California. Therefore,
for the precaution sake, no new TODoXIN data were presented in the
12th International AIDS Conference in Geneva.